ZA200400066B - Calcium phosphate delivery vehicles for osteoinductive proteins - Google Patents
Calcium phosphate delivery vehicles for osteoinductive proteins Download PDFInfo
- Publication number
- ZA200400066B ZA200400066B ZA200400066A ZA200400066A ZA200400066B ZA 200400066 B ZA200400066 B ZA 200400066B ZA 200400066 A ZA200400066 A ZA 200400066A ZA 200400066 A ZA200400066 A ZA 200400066A ZA 200400066 B ZA200400066 B ZA 200400066B
- Authority
- ZA
- South Africa
- Prior art keywords
- phosphate
- bmp
- composition
- bone
- calcium
- Prior art date
Links
- 239000001506 calcium phosphate Substances 0.000 title claims description 110
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims description 109
- 235000011010 calcium phosphates Nutrition 0.000 title claims description 102
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims description 100
- 108090000623 proteins and genes Proteins 0.000 title claims description 31
- 102000004169 proteins and genes Human genes 0.000 title claims description 30
- 230000002138 osteoinductive effect Effects 0.000 title description 9
- 239000000463 material Substances 0.000 claims description 136
- 229960001714 calcium phosphate Drugs 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 63
- 210000000988 bone and bone Anatomy 0.000 claims description 62
- 229910019142 PO4 Inorganic materials 0.000 claims description 41
- 239000010452 phosphate Substances 0.000 claims description 40
- 239000011575 calcium Substances 0.000 claims description 36
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 35
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 33
- 229960005069 calcium Drugs 0.000 claims description 32
- 229910052791 calcium Inorganic materials 0.000 claims description 32
- 235000001465 calcium Nutrition 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000013543 active substance Substances 0.000 claims description 28
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 19
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 19
- 230000000576 supplementary effect Effects 0.000 claims description 18
- 230000002188 osteogenic effect Effects 0.000 claims description 14
- -1 si Ik Proteins 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 239000007789 gas Substances 0.000 claims description 12
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 8
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 8
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 230000007547 defect Effects 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- 210000002805 bone matrix Anatomy 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 4
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 4
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 102000016970 Follistatin Human genes 0.000 claims description 4
- 108010014612 Follistatin Proteins 0.000 claims description 4
- 102100035368 Growth/differentiation factor 6 Human genes 0.000 claims description 4
- 101710204281 Growth/differentiation factor 6 Proteins 0.000 claims description 4
- 229910052786 argon Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 102000006533 chordin Human genes 0.000 claims description 4
- 108010008846 chordin Proteins 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 3
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 3
- 241000202252 Cerberus Species 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 claims description 3
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229910052587 fluorapatite Inorganic materials 0.000 claims description 3
- 229940077441 fluorapatite Drugs 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 2
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 2
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 claims description 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical group [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims 2
- 230000000921 morphogenic effect Effects 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 230000001175 peptic effect Effects 0.000 claims 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000008187 granular material Substances 0.000 description 24
- 239000002243 precursor Substances 0.000 description 21
- 239000002131 composite material Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 229940090044 injection Drugs 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 239000011159 matrix material Substances 0.000 description 15
- 239000000376 reactant Substances 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007943 implant Substances 0.000 description 11
- 239000004568 cement Substances 0.000 description 10
- 230000000975 bioactive effect Effects 0.000 description 9
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000919 ceramic Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 5
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229920001432 poly(L-lactide) Polymers 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002639 bone cement Substances 0.000 description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 210000002082 fibula Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000008468 bone growth Effects 0.000 description 3
- 239000000316 bone substitute Substances 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 102000045246 noggin Human genes 0.000 description 3
- 108700007229 noggin Proteins 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000049 Carbon (fiber) Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000010669 acid-base reaction Methods 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003462 bioceramic Substances 0.000 description 2
- 229920013641 bioerodible polymer Polymers 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000004917 carbon fiber Substances 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000004682 monohydrates Chemical group 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- VSCBATMPTLKTOV-UHFFFAOYSA-N 2-tert-butylimino-n,n-diethyl-1,3-dimethyl-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound CCN(CC)P1(=NC(C)(C)C)N(C)CCCN1C VSCBATMPTLKTOV-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102100025745 Cerberus Human genes 0.000 description 1
- 101710010675 Cerberus Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000027587 GPCRs class F Human genes 0.000 description 1
- 108091008884 GPCRs class F Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 101100175313 Mus musculus Gdf3 gene Proteins 0.000 description 1
- 101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 241001561899 Otomys Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229940057324 biore Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000045896 human BMP2 Human genes 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000004515 macrogranule Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011738 major mineral Substances 0.000 description 1
- 235000011963 major mineral Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000150 monocalcium phosphate Inorganic materials 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920005583 poly(anhydride-co-imide) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000012779 reinforcing material Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/005—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/14—Post-treatment to improve physical properties
- A61L17/145—Coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
- Dental Prosthetics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29681801P | 2001-06-08 | 2001-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200400066B true ZA200400066B (en) | 2007-04-25 |
Family
ID=23143697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200400066A ZA200400066B (en) | 2001-06-08 | 2004-01-06 | Calcium phosphate delivery vehicles for osteoinductive proteins |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7413753B2 (fr) |
| EP (2) | EP1404346B1 (fr) |
| JP (5) | JP4414218B2 (fr) |
| KR (3) | KR20040019300A (fr) |
| CN (2) | CN101239182B (fr) |
| AR (1) | AR034347A1 (fr) |
| AU (1) | AU2002314928B2 (fr) |
| BR (1) | BRPI0210282B8 (fr) |
| CA (2) | CA2449713C (fr) |
| HU (1) | HU230046B1 (fr) |
| IL (3) | IL159136A0 (fr) |
| MX (1) | MXPA03011236A (fr) |
| NO (1) | NO333548B1 (fr) |
| NZ (1) | NZ530435A (fr) |
| PL (1) | PL216040B1 (fr) |
| TW (1) | TWI267378B (fr) |
| WO (1) | WO2002100331A2 (fr) |
| ZA (1) | ZA200400066B (fr) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687462B2 (en) | 1999-10-05 | 2010-03-30 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
| DE10032220A1 (de) | 2000-07-03 | 2002-01-24 | Sanatis Gmbh | Magnesium-ammonium-phosphat-Zemente, deren Herstellung und Verwendung |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| JP4614661B2 (ja) * | 2002-02-08 | 2011-01-19 | ワイス | 生体活性因子を含有する処方物およびそれを使用する方法 |
| TW200400062A (en) * | 2002-04-03 | 2004-01-01 | Mathys Medizinaltechnik Ag | Kneadable, pliable bone replacement material |
| US7273523B2 (en) | 2002-06-07 | 2007-09-25 | Kyphon Inc. | Strontium-apatite-cement-preparations, cements formed therefrom, and uses thereof |
| US20070026069A1 (en) * | 2003-03-28 | 2007-02-01 | Shastri Venkatram P | Biommetic hierarchies using functionalized nanoparticles as building blocks |
| US20040199256A1 (en) * | 2003-04-04 | 2004-10-07 | Chao-Jan Wang | Support device for supporting between spinal vertebrae |
| AU2004229502C1 (en) * | 2003-04-11 | 2011-02-24 | Etex Corporation | Osteoinductive bone material |
| AU2004272072B2 (en) * | 2003-09-12 | 2010-07-08 | Etex Corporation | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| EP1744794A2 (fr) * | 2004-03-05 | 2007-01-24 | The Trustees Of Columbia University In The City Of New York | Squelette composite d'hydrogel ceramique/polymere pour une reparation osteochondrale |
| US7767221B2 (en) * | 2004-03-05 | 2010-08-03 | The Trustees Of Columbia University In The City Of New York | Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone |
| CA2562675A1 (fr) * | 2004-04-15 | 2005-12-15 | Etex Corporation | Pates de phosphate de calcium a durcissement retarde |
| KR20060134223A (ko) | 2004-04-27 | 2006-12-27 | 키폰 인크. | 뼈 대체 조성물 및 사용 방법 |
| US20060074422A1 (en) * | 2004-09-27 | 2006-04-06 | Story Brooks J | Suture anchor and void filler combination |
| US20060089723A1 (en) * | 2004-10-25 | 2006-04-27 | Murphy Kieran P | Method for bone augmentation |
| US8852240B2 (en) * | 2004-10-25 | 2014-10-07 | Kieran Murphy, Llc | Methods and compositions for fostering and preserving bone growth |
| US7651701B2 (en) * | 2005-08-29 | 2010-01-26 | Sanatis Gmbh | Bone cement composition and method of making the same |
| US20070248675A1 (en) * | 2005-09-08 | 2007-10-25 | Gwangju Institute Of Science And Technology | Composite comprising polysaccharide-functionalized nanoparticle and hydrogel matrix, a drug delivery system and a bone defect replacement matrix for sustained release comprising the same, and the preparation method thereof |
| US8920827B2 (en) * | 2005-10-21 | 2014-12-30 | Wake Forest University Health Sciences | Keratin bioceramic compositions |
| US8147860B2 (en) | 2005-12-06 | 2012-04-03 | Etex Corporation | Porous calcium phosphate bone material |
| US10300167B2 (en) * | 2006-03-24 | 2019-05-28 | Cabertech, Inc. | Functionalized calcium phosphate artificial bone and joint compositions and methods of use and manufacture |
| US20070255422A1 (en) * | 2006-04-25 | 2007-11-01 | Mei Wei | Calcium phosphate polymer composite and method |
| US7754005B2 (en) | 2006-05-02 | 2010-07-13 | Kyphon Sarl | Bone cement compositions comprising an indicator agent and related methods thereof |
| US7507286B2 (en) * | 2006-06-08 | 2009-03-24 | Sanatis Gmbh | Self-foaming cement for void filling and/or delivery systems |
| WO2008013900A2 (fr) * | 2006-07-26 | 2008-01-31 | The Regents Of The University Of California | Composition d'amplification d'activité ostéogène |
| US8722783B2 (en) * | 2006-11-30 | 2014-05-13 | Smith & Nephew, Inc. | Fiber reinforced composite material |
| US20100047309A1 (en) * | 2006-12-06 | 2010-02-25 | Lu Helen H | Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods |
| WO2009131553A2 (fr) * | 2006-12-29 | 2009-10-29 | Osteogenex Inc. | Procédés de modification de croissance osseuse par administration d'antagoniste ou d'agoniste sost ou wise |
| US8753391B2 (en) | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
| US20080241256A1 (en) * | 2007-03-30 | 2008-10-02 | Liisa Kuhn | Targeted active agent delivery system based on calcium phosphate nanoparticles |
| AU2007352435B2 (en) * | 2007-04-27 | 2012-01-19 | Unigene Laboratories, Inc. | Methods and compositions for fostering and preserving bone growth |
| US20090081276A1 (en) * | 2007-08-13 | 2009-03-26 | Eben Alsberg | Bioresorbable implant composition |
| US20090061002A1 (en) | 2007-09-05 | 2009-03-05 | Venbrocks Rudolf A | Calcium phospate based delivery of growth and differentiation factors to compromised bone |
| US7968616B2 (en) * | 2008-04-22 | 2011-06-28 | Kyphon Sarl | Bone cement composition and method |
| TWI381857B (zh) * | 2008-12-10 | 2013-01-11 | Univ Taipei Medical | 口腔保健用之非晶性磷酸鈣之製備方法及其組成物 |
| CA2763466C (fr) | 2009-05-26 | 2019-02-26 | B. Chia Soo | Peptide de la fibromoduline |
| US9636109B2 (en) | 2009-07-22 | 2017-05-02 | Wisconsin Alumni Research Foundation | Biologically active sutures for regenerative medicine |
| US9937128B2 (en) | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| US20110046240A1 (en) * | 2009-08-24 | 2011-02-24 | Keizer Timothy S | Calcium-based carrier particles |
| US20110046239A1 (en) * | 2009-08-24 | 2011-02-24 | Keiser Bruce A | Calcium based carrier particles |
| US20110046241A1 (en) * | 2009-08-24 | 2011-02-24 | Keizer Timothy S | Calcium based carrier particles |
| US20110046238A1 (en) * | 2009-08-24 | 2011-02-24 | Keiser Bruce A | Calcium based carrier particles |
| WO2011058443A1 (fr) * | 2009-11-13 | 2011-05-19 | Barralet Jake E | Procédé et dispositif pour induire une biominéralisation du collagène |
| US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
| US8388887B2 (en) | 2010-04-12 | 2013-03-05 | Biomet Manufacturing Corp. | Methods for making textured ceramic implants |
| TWI579007B (zh) | 2010-07-02 | 2017-04-21 | 艾格諾福斯保健公司 | 骨再生材料之用途 |
| WO2012024573A2 (fr) | 2010-08-19 | 2012-02-23 | The Regents Of The University Of California | Compositions comprenant des cellules souches périvasculaires et la protéine nell-1 |
| US8551525B2 (en) | 2010-12-23 | 2013-10-08 | Biostructures, Llc | Bone graft materials and methods |
| WO2012093939A1 (fr) | 2011-01-05 | 2012-07-12 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Particules comprenant du phosphate de calcium et utilisation associée |
| WO2012177759A1 (fr) | 2011-06-20 | 2012-12-27 | Rdc Holdings, Llc | Système et procédé de réparation d'articulations |
| US8998925B2 (en) | 2011-06-20 | 2015-04-07 | Rdc Holdings, Llc | Fixation system for orthopedic devices |
| WO2014015247A1 (fr) | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Composés de difluorolactame comme agonistes sélectifs du récepteur ep4, destinés à être utilisés dans le traitement de maladies et d'affections médiées par ep4 |
| DK2958603T3 (en) | 2013-02-20 | 2018-07-16 | Bone Support Ab | IMPROVED CURE FOR HARDWARE BONE COMPENSATION |
| CN105120863B (zh) | 2013-03-14 | 2021-06-04 | 奥斯特克有限公司 | 促进骨生长的烷基胺骆驼蓬碱衍生物 |
| EP2983643A4 (fr) | 2013-04-12 | 2016-12-28 | Univ Columbia | Procédés pour l'écotropisme de cellules hôtes et la régénération de pulpe dentaire |
| KR20160048054A (ko) * | 2013-07-19 | 2016-05-03 | 카이맨 케미칼 컴파니 인코포레이티드 | 골 성장의 촉진을 위한 방법, 시스템 및 조성물 |
| JP6145366B2 (ja) * | 2013-09-10 | 2017-06-07 | HOYA Technosurgical株式会社 | リン酸カルシウム硬化性組成物 |
| EP3185919A1 (fr) * | 2014-08-28 | 2017-07-05 | Bioventus LLC | Substrats d'ostéoinduction perfectionnés et leurs procédés de fabrication |
| KR101597203B1 (ko) * | 2014-09-26 | 2016-02-24 | 한국화학연구원 | 생분해성 폴리머 및 수산화아파타이트를 포함하는 복합 소재 및 이의 제조방법 |
| US10130678B2 (en) | 2014-12-29 | 2018-11-20 | Bioventus, LLC. | Systems and methods for improved delivery of osteoinductive molecules in bone repair |
| US10238507B2 (en) | 2015-01-12 | 2019-03-26 | Surgentec, Llc | Bone graft delivery system and method for using same |
| US20160374904A1 (en) * | 2015-06-23 | 2016-12-29 | South Dakota Board Of Regents | Sequential Material Deposition for Remineralization and Desensitization of Teeth |
| ES2672265B1 (es) * | 2016-11-07 | 2019-04-10 | Inst Biomecanico De Barcelona S L | Dispositivo para fusion intervertebral que comprende un tornillo de estabilizacion intervertebral y una composicion para remodelacion osea |
| CN106822991B (zh) * | 2017-03-13 | 2019-09-27 | 深圳市英汉斯科技有限公司 | 小分子肽生物骨修复材料及其制备方法 |
| WO2018187344A1 (fr) * | 2017-04-03 | 2018-10-11 | Wisconsin Alumni Research Foundation | Microparticules enrobées de minéraux destinées à l'administration prolongée de molécules biologiquement actives |
| US10687828B2 (en) | 2018-04-13 | 2020-06-23 | Surgentec, Llc | Bone graft delivery system and method for using same |
| US11116647B2 (en) | 2018-04-13 | 2021-09-14 | Surgentec, Llc | Bone graft delivery system and method for using same |
| CN108815580B (zh) * | 2018-07-23 | 2019-11-12 | 吴容思 | 一种可调控降解的磷酸钙骨水泥及其制备方法 |
| CA3109104A1 (fr) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Composes .beta.-carboline fluores |
| CA3108714A1 (fr) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | Composes pyrrolo-dipyridine |
| US12428484B2 (en) | 2018-12-06 | 2025-09-30 | Alexion Pharmaceuticals, Inc. | Anti-ALK2 antibodies and uses thereof |
| EP3908229A4 (fr) * | 2019-01-10 | 2022-08-31 | University of Utah Research Foundation | Exposé de structures contenant de la fluorapatite concernant la recherche commanditée par le gouvernement fédéral |
| CN110064071B (zh) * | 2019-04-12 | 2021-09-10 | 西安理工大学 | 一种可膨胀无机骨水泥的制备方法 |
| CN114569732B (zh) * | 2022-01-24 | 2023-09-01 | 国家纳米科学中心 | 一种纳米药物及其制备方法和应用 |
Family Cites Families (259)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2465357A (en) | 1944-08-14 | 1949-03-29 | Upjohn Co | Therapeutic sponge and method of making |
| CH563767A5 (fr) | 1973-01-30 | 1975-07-15 | Pheulpin Jean | |
| US4468464A (en) | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
| DE2657370C2 (de) | 1976-12-17 | 1982-11-11 | Hans Dr.med. Dr.med.dent. 8000 München Scheicher | Mittel zum Bedecken und/oder Ausfüllen von Knochendefekten |
| US4159358A (en) * | 1977-05-19 | 1979-06-26 | Board Of Regents, State Of Florida | Method of bonding a bioglass to metal |
| DE2732848A1 (de) | 1977-07-18 | 1979-02-08 | Schering Ag | Diurethane, herbizide mittel enthaltend diese verbindungen sowie verfahren zu ihrer herstellung |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| US4761471A (en) | 1980-08-04 | 1988-08-02 | The Regents Of The University Of California | Bone morphogenetic protein composition |
| US4619989A (en) | 1981-05-05 | 1986-10-28 | The Regents Of The University Of Cal. | Bone morphogenetic protein composition |
| US4294753A (en) | 1980-08-04 | 1981-10-13 | The Regents Of The University Of California | Bone morphogenetic protein process |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| EP0061840A3 (fr) | 1981-03-30 | 1983-08-24 | Imperial Chemical Industries Plc | Composés de triazole, procédé pour leur préparation, leur application comme fungicides de plantes et leurs compositions fongicides |
| US4727028A (en) | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4472840A (en) | 1981-09-21 | 1984-09-25 | Jefferies Steven R | Method of inducing osseous formation by implanting bone graft material |
| US4474181A (en) | 1982-02-18 | 1984-10-02 | Schenck Robert R | Method and apparatus for anastomosing small blood vessels |
| USRE33161E (en) | 1982-04-29 | 1990-02-06 | American Dental Association Health Foundation | Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements |
| USRE33221E (en) | 1982-04-29 | 1990-05-22 | American Dental Association Health Foundation | Dental restorative cement pastes |
| DE3382562D1 (de) | 1982-09-24 | 1992-06-25 | Us Health | Wiederherstellung von gewebe bei tieren. |
| IL68218A (en) | 1983-03-23 | 1985-12-31 | Univ Ramot | Compositions for cartilage repair comprising embryonal chondrocytes |
| US4434094A (en) | 1983-04-12 | 1984-02-28 | Collagen Corporation | Partially purified osteogenic factor and process for preparing same from demineralized bone |
| CA1229789A (fr) | 1983-06-06 | 1987-12-01 | David Baylink | Polypeptides stimulant la croissance du tissu osseaux |
| US4795804A (en) | 1983-08-16 | 1989-01-03 | The Regents Of The University Of California | Bone morphogenetic agents |
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| GB8334498D0 (en) | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Compounds |
| US4804744A (en) | 1984-01-04 | 1989-02-14 | International Genetic Engineering, Inc. | Osteogenic factors |
| ZA848495B (en) | 1984-01-31 | 1985-09-25 | Idaho Res Found | Production of polypeptides in insect cells |
| US4563489A (en) * | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| US4608199A (en) | 1984-03-20 | 1986-08-26 | Arnold Caplan | Bone protein purification process |
| US4662884A (en) | 1984-04-25 | 1987-05-05 | University Of Utah Research Foundation | Prostheses and methods for promoting nerve regeneration |
| US4596574A (en) | 1984-05-14 | 1986-06-24 | The Regents Of The University Of California | Biodegradable porous ceramic delivery system for bone morphogenetic protein |
| CA1341617C (fr) | 1984-06-08 | 2011-06-28 | Henry George Burger | Inhibine extracte de liquide folliculaire ovarien |
| US4868161A (en) | 1984-06-29 | 1989-09-19 | City Of Hope | Method for promoting nerve regeneration |
| NZ228031A (en) | 1984-07-06 | 1991-12-23 | Sandoz Ltd | Primate gm-csf and method of extraction |
| AU4549985A (en) | 1984-07-13 | 1986-02-10 | Economix Kozgazdasz Egyetemi Kisszovetkezet | Process for the preparation of a pharmaceutical composition influencing the tissue metabolism and having a regenerating action |
| US4843063A (en) | 1984-07-16 | 1989-06-27 | Collagen Corporation | Polypeptide cartilage-inducing factors found in bone |
| DE3588058T3 (de) | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Knorpel-induzierende Polypeptid-Faktoren aus Knochen |
| US4627982A (en) | 1984-07-16 | 1986-12-09 | Collagen Corporation | Partially purified bone-inducing factor |
| ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| US4769328A (en) | 1984-10-12 | 1988-09-06 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in yeast |
| US5187263A (en) | 1984-10-12 | 1993-02-16 | Zymogenetics, Inc. | Expression of biologically active PDGE analogs in eucaryotic cells |
| US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
| WO1986004067A1 (fr) | 1984-12-27 | 1986-07-17 | Suntory Limited | Procede de purification d'un interferon |
| US4886747A (en) | 1985-03-22 | 1989-12-12 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
| US4681763A (en) | 1985-06-11 | 1987-07-21 | University Of Medicine And Dentistry Of New Jersey | Composition for stimulating bone growth |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US4740587A (en) | 1985-07-18 | 1988-04-26 | The Salk Institute For Biological Studies | Inhibin and method of purifying same |
| US5089396A (en) | 1985-10-03 | 1992-02-18 | Genentech, Inc. | Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| NZ217727A (en) | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
| US5215893A (en) | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
| US4798885A (en) | 1986-02-07 | 1989-01-17 | Genentech, Inc. | Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain |
| US4737578A (en) | 1986-02-10 | 1988-04-12 | The Salk Institute For Biological Studies | Human inhibin |
| EP0241809B1 (fr) | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Association synergétique d'amantadine et de sélégiline |
| US4758233A (en) | 1986-04-22 | 1988-07-19 | N.J. Phillips TPY. Limited | Cream applicator |
| NL8601328A (nl) * | 1986-05-23 | 1987-12-16 | Langen Research | Inrichting voor het met een massa, in het bijzonder pasteuze massa, injekteren van vlees. |
| US4839215A (en) * | 1986-06-09 | 1989-06-13 | Ceramed Corporation | Biocompatible particles and cloth-like article made therefrom |
| US5366875A (en) | 1986-07-01 | 1994-11-22 | Genetics Institute, Inc. | Methods for producing BMP-7 proteins |
| US5939388A (en) | 1986-07-01 | 1999-08-17 | Rosen; Vicki A. | Methods of administering BMP-5 compositions |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5187076A (en) | 1986-07-01 | 1993-02-16 | Genetics Institute, Inc. | DNA sequences encoding BMP-6 proteins |
| US5459047A (en) | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
| US6432919B1 (en) | 1986-07-01 | 2002-08-13 | Genetics Institute, Inc. | Bone morphogenetic protein-3 and compositions |
| US4877864A (en) | 1987-03-26 | 1989-10-31 | Genetics Institute, Inc. | Osteoinductive factors |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5108922A (en) | 1986-07-01 | 1992-04-28 | Genetics Institute, Inc. | DNA sequences encoding BMP-1 products |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| US5543394A (en) | 1986-07-01 | 1996-08-06 | Genetics Institute, Inc. | Bone morphogenetic protein 5(BMP-5) compositions |
| US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
| ZA874681B (en) | 1986-07-01 | 1988-04-27 | Genetics Inst | Novel osteoinductive factors |
| US5106748A (en) | 1986-07-01 | 1992-04-21 | Genetics Institute, Inc. | Dna sequences encoding 5 proteins |
| US5019087A (en) | 1986-10-06 | 1991-05-28 | American Biomaterials Corporation | Nerve regeneration conduit |
| US5124316A (en) | 1986-11-14 | 1992-06-23 | President And Fellows Of Harvard College | Method for periodontal regeneration |
| US4798684A (en) | 1987-06-09 | 1989-01-17 | The Lubrizol Corporation | Nitrogen containing anti-oxidant compositions |
| US5457092A (en) | 1987-07-30 | 1995-10-10 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Methods of promoting bone growth in mammals comprising administration of modified parathyroid hormone |
| US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5202120A (en) | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
| US5147399A (en) | 1988-02-01 | 1992-09-15 | Dellon Arnold L | Method of treating nerve defects through use of a bioabsorbable surgical device |
| IT1215881B (it) | 1988-02-16 | 1990-02-22 | Giancarlo Foresti | Sussidio chirurgico ad azione osteotropa. |
| US5028582A (en) | 1988-04-07 | 1991-07-02 | Matsushita Electric Industrial Co., Ltd. | Receiving sheets for dye transfer type thermal printing |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| JP2522568B2 (ja) | 1988-04-08 | 1996-08-07 | ストライカー・コーポレーション | 骨形成デバイス |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US6586388B2 (en) | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
| US4968590A (en) | 1988-04-08 | 1990-11-06 | Stryker Corporation | Osteogenic proteins and polypeptides |
| AU645244B2 (en) | 1988-04-08 | 1994-01-13 | Genetics Institute, Llc | Bone and cartilage inductive compositions |
| US5108753A (en) | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
| US5354557A (en) | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
| US5258494A (en) | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
| US5053212A (en) | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| US6005162A (en) * | 1988-04-20 | 1999-12-21 | Norian Corporation | Methods of repairing bone |
| US6002065A (en) * | 1988-04-20 | 1999-12-14 | Norian Corporation | Kits for preparing calcium phosphate minerals |
| US5129905A (en) | 1988-04-20 | 1992-07-14 | Norian Corporation | Methods for in situ prepared calcium phosphate minerals |
| US5962028A (en) | 1988-04-20 | 1999-10-05 | Norian Corporation | Carbonated hydroxyapatite compositions and uses |
| GB8809419D0 (en) | 1988-04-21 | 1988-05-25 | Pragnell I | Stem cell inhibitors |
| US5024841A (en) | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5071834A (en) | 1988-09-16 | 1991-12-10 | Genentech, Inc. | Purified activin B composition |
| US5284756A (en) | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
| US5106626A (en) | 1988-10-11 | 1992-04-21 | International Genetic Engineering, Inc. | Osteogenic factors |
| US4955892A (en) | 1988-10-24 | 1990-09-11 | Louisiana State University | Neural cell adhesion protein nerve prosthesis |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5011486A (en) | 1988-11-18 | 1991-04-30 | Brown University Research Foundation | Composite nerve guidance channels |
| US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| US4920962A (en) | 1988-11-23 | 1990-05-01 | Claude Proulx | Splint-like element for use in end-to-end nerve suture |
| US5217867A (en) | 1988-11-30 | 1993-06-08 | The Salk Institute For Biological Studies | Receptors: their identification, characterization, preparation and use |
| US5457047A (en) | 1989-02-23 | 1995-10-10 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | DNA Sequences coding for PTH variants, PTH variants, expression vector, bacterial host, use and therapeutic composition |
| DE69031939T2 (de) | 1989-03-28 | 1998-09-10 | Genetics Institute, Inc., Cambridge, Mass. | Osteoinduktive zusammensetzungen |
| US5026381A (en) | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
| US4963146A (en) | 1989-04-20 | 1990-10-16 | Colla-Tec Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| JPH03151877A (ja) | 1989-06-02 | 1991-06-28 | Chiron Corp | 骨カルシウム沈着因子 |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| AU5958090A (en) | 1989-06-29 | 1991-01-17 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1 |
| CA2020729A1 (fr) | 1989-07-19 | 1991-01-20 | Michael C. Kiefer | Proteine morphogenetique des os |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| CA2064878A1 (fr) | 1989-08-21 | 1991-02-22 | Hanne Bentz | Proteine specifique des os |
| US5422340A (en) | 1989-09-01 | 1995-06-06 | Ammann; Arthur J. | TGF-βformulation for inducing bone growth |
| CA2024629C (fr) | 1989-09-06 | 2001-07-24 | Taiheiyo Cement Corporation | Proteine morphogenique osseuse dactylethre laevis, adn l'encodant et son utilisation |
| CA2064558C (fr) | 1989-09-25 | 2001-01-30 | Ian B. Pragnell | Methode d'inhibition de la croissance de cellules souches |
| WO1991005802A1 (fr) | 1989-10-17 | 1991-05-02 | Creative Biomolecules, Inc. | Dispositifs osteogenes |
| US5236456A (en) * | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
| US5215895A (en) | 1989-11-22 | 1993-06-01 | Genetics Institute, Inc. | Dna encoding a mammalian cytokine, interleukin-11 |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5166190A (en) | 1990-01-08 | 1992-11-24 | Genentech, Inc. | Method for increasing fertility in males |
| US5187086A (en) | 1990-01-26 | 1993-02-16 | Scripps Clinic And Research Foundation | Molecules with antibody combining sites that catalyze hydrolysis reactions through use of a charged hapten |
| US5492697A (en) | 1990-03-05 | 1996-02-20 | Board Of Regents, Univ. Of Texas System | Biodegradable implant for fracture nonunions |
| US5256418A (en) | 1990-04-06 | 1993-10-26 | Organogenesis, Inc. | Collagen constructs |
| EP0452859B1 (fr) * | 1990-04-18 | 1997-02-26 | Sharp Kabushiki Kaisha | Dispositif de fac-similé avec poste téléphonique sans fil |
| US5290271A (en) | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
| US5688678A (en) | 1990-05-16 | 1997-11-18 | Genetics Institute, Inc. | DNA encoding and methods for producing BMP-8 proteins |
| JPH06500991A (ja) | 1990-05-16 | 1994-01-27 | ジェネティックス・インスティテュート・インコーポレイテッド | 骨および軟骨誘導蛋白質 |
| WO1991017777A2 (fr) | 1990-05-22 | 1991-11-28 | University Of Florida | Compositions de verre bioactives injectables et procede de reconstitution de tissus |
| US5168050A (en) | 1990-05-24 | 1992-12-01 | Genentech, Inc. | Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion |
| US5218090A (en) | 1990-06-12 | 1993-06-08 | Warner-Lambert Company | EGF receptor truncates |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| CA2091266A1 (fr) | 1990-09-14 | 1992-03-15 | Patricia Tekamp-Olson | Expression de proteines macrophages inductibles dans des cellules de levure |
| EP0550625B1 (fr) | 1990-09-26 | 2003-11-05 | Genetics Institute, LLC | Derives bmp-5 |
| WO1992007004A1 (fr) | 1990-10-18 | 1992-04-30 | Creative Biomolecules, Inc. | Proteine osteogenique |
| US5206028A (en) | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
| US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| JPH06500574A (ja) | 1991-05-10 | 1994-01-20 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | アクチビン/TGF―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生 |
| US5229495A (en) | 1991-06-18 | 1993-07-20 | Ludwig Institute For Cancer Research | Substantially pure receptor like TGF-β 1 binding molecules and uses thereof |
| US5216126A (en) | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
| WO1993000050A1 (fr) | 1991-06-21 | 1993-01-07 | Genetics Institute, Inc. | Compositions pharmaceutiques de proteines osteogeniques |
| AU652472B2 (en) | 1991-06-25 | 1994-08-25 | Genetics Institute, Llc | BMP-9 compositions |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
| US5306307A (en) | 1991-07-22 | 1994-04-26 | Calcitek, Inc. | Spinal disk implant |
| ATE192931T1 (de) | 1991-08-30 | 2000-06-15 | Creative Biomolecules Inc | Morphogen-induzierte modulation von entzündlichen antworten |
| DE69233559T2 (de) | 1991-08-30 | 2006-08-31 | Curis, Inc., Cambridge | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| US5171579A (en) | 1991-10-11 | 1992-12-15 | Genetics Institute, Inc. | Formulations of blood clot-polymer matrix for delivery of osteogenic proteins |
| JP2984112B2 (ja) | 1991-10-31 | 1999-11-29 | 京セラ株式会社 | 骨充填材 |
| ATE238417T1 (de) | 1991-11-04 | 2003-05-15 | Inst Genetics Llc | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung |
| DE69228949T2 (de) | 1991-11-22 | 1999-09-16 | Auckland Uniservices Ltd., Auckland | Tgf-beta zur verbesserung der regeneration von neuronalem gewebe |
| FI943024L (fi) | 1991-12-23 | 1994-06-22 | British Bio Technology | Kantasoluja estävät proteiinit |
| SE469653B (sv) | 1992-01-13 | 1993-08-16 | Lucocer Ab | Poroest implantat |
| DK0625989T3 (da) | 1992-02-12 | 2000-06-26 | Bioph Biotech Entw Pharm Gmbh | DNA-sekvenser kodende for hidtil ukendte vækst-/differentieringsfaktorer |
| EP1120439B1 (fr) | 1992-02-28 | 2004-06-16 | Cohesion Technologies, Inc. | Compositions céramiques injectables et leur procédé de préparation et d'utilisation |
| WO1993019177A1 (fr) | 1992-03-18 | 1993-09-30 | The General Hospital Corporation | QUATRE NOUVEAUX RECEPTEURS APPARTENANT A LA FAMILLE DES RECEPTEURS TGF-$g(b) |
| IT1259090B (it) | 1992-04-17 | 1996-03-11 | Fidia Spa | Biomaterialli per protesi d'osso |
| US5550176A (en) * | 1992-04-17 | 1996-08-27 | Ucar Carbon Technology Corporation | Room temperature setting carbonaceous cement with increased electrical conductivity and flexural strength |
| IT1259100B (it) | 1992-05-20 | 1996-03-11 | Lanfranco Callegaro | Uso di idrogeli per il bloccaggio di sistemi protesici |
| IL106278A0 (en) | 1992-07-13 | 1993-11-15 | Sumitomo Metal Ind | Bone formation-inducing protein |
| EP0653942B2 (fr) | 1992-07-31 | 2007-03-07 | Curis, Inc. | Regeneration et reparation du systeme nerveux induites par morphogene |
| ZA936478B (en) | 1992-09-03 | 1994-09-30 | Regeneron Pharma | Dorsal tissue affecting factor and compositions |
| ES2114073T3 (es) | 1992-09-16 | 1998-05-16 | Creative Biomolecules Inc | Regeneracion del higado inducida por morfogenes. |
| KR950704485A (ko) | 1992-11-17 | 1995-11-20 | 로이드 제이. 오울드·에드워드 에이, 맥더모 2세 | 액티빈 리셉터-유사 키나제, 세린 트레오닌 키나제 도메인을 갖는 단백질 및 이들의 용도(activin receptor-like kinases, proteins having serine threonine kinase domains and their use) |
| EP0678101A4 (fr) | 1993-01-12 | 1997-07-16 | Univ Johns Hopkins Med | Facteur-9 de croissance et de differentiation. |
| WO1994015965A1 (fr) | 1993-01-12 | 1994-07-21 | Johns Hopkins University School Of Medicine | Facteur-3 de croissance et de differenciation |
| JP3645258B2 (ja) | 1993-01-12 | 2005-05-11 | ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | 増殖分化因子−5 |
| US5420243A (en) | 1993-01-26 | 1995-05-30 | Celtrix Pharmaceuticals, Inc. | Biologically active TGF-β2 peptides |
| DK0690873T3 (da) | 1993-03-19 | 2003-09-29 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-8 |
| GB9308060D0 (en) | 1993-04-19 | 1993-06-02 | Cancer Res Campaign Tech | Stem cell inhibitor |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| EP0698095B1 (fr) | 1993-05-12 | 2004-04-28 | Genetics Institute, LLC | Compositions de bmp-10 |
| BR9406715A (pt) | 1993-05-12 | 1996-02-06 | Genetics Inst | Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica |
| EP0626451A3 (fr) | 1993-05-27 | 1997-11-05 | Takeda Chemical Industries, Ltd. | Hétérodimères d'une superfamille de TGF-bêta |
| US5447725A (en) | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
| CA2165776A1 (fr) | 1993-07-09 | 1995-01-19 | The Johns Hopkins University School Of Medicine | Facteur 6 de differentiation de la croissance |
| EP0717633A4 (fr) | 1993-07-09 | 1998-05-20 | Univ Johns Hopkins Med | Facteur 7 de differenciation de la croissance |
| DK0716610T3 (da) | 1993-08-26 | 2006-09-04 | Genetics Inst Llc | Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering |
| US5455041A (en) | 1993-09-13 | 1995-10-03 | Research Foundation Of State University Of New York At Buffalo | Method for inducing periodontal tissue regeneration |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| EP0725796A4 (fr) | 1993-10-08 | 1999-12-01 | Univ Johns Hopkins | Facteur 10 de la differentiation de croissance |
| DE69434934D1 (de) | 1993-10-14 | 2007-04-12 | Harvard College | Verfahren zur induzierung und zur erhaltung neuronalen zellen |
| US5789543A (en) * | 1993-12-30 | 1998-08-04 | President And Fellows Of Harvard College | Vertebrate embryonic pattern-inducing proteins and uses related thereto |
| WO1995011707A1 (fr) | 1993-10-28 | 1995-05-04 | Thm Biomedical, Inc. | Procede et dispositif ameliores permettant de traiter et guerir une cavite osseuse |
| USH1532H (en) | 1993-11-03 | 1996-05-07 | Genetics Institute, Inc. | Adaption of mammalian cell lines to high cell densities |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| US6027919A (en) | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
| DE69434651T2 (de) | 1993-12-07 | 2007-03-08 | Genetics Institute, Inc., Cambridge | Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen |
| US5439904A (en) | 1993-12-07 | 1995-08-08 | Synphar Laboratories, Inc. | 2-spiro(2'-spirocycloalkyl)cyclopropyl cephalosporin sulfones as antiinflammatory and antigenerative agents |
| US5556767A (en) | 1993-12-22 | 1996-09-17 | Human Genome Sciences, Inc. | Polynucleotide encoding macrophage inflammatory protein γ |
| WO1995018856A1 (fr) | 1993-12-30 | 1995-07-13 | President And Fellows Of Harvard College | Proteines de type herisson induisant une structure embryonnaire chez les vertebres |
| JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | TGF−βスーパーファミリー蛋白質をコードするヒト新規cDNA |
| JP3424049B2 (ja) | 1994-03-09 | 2003-07-07 | 山之内製薬株式会社 | 骨形成用移植体 |
| US5723331A (en) | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
| CA2194660C (fr) | 1994-07-08 | 2009-09-29 | Se-Jin Lee | Facteur 11 de differentiation de croissance |
| DK0770089T3 (da) | 1994-07-13 | 2000-10-23 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-12 |
| US5520923A (en) | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| US5693779A (en) | 1994-11-08 | 1997-12-02 | The United States Of America As Represented By The Department Of Health And Human Services | Production and use of anti-dorsalizing morphogenetic protein |
| US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| WO1996018924A1 (fr) | 1994-12-15 | 1996-06-20 | Olympus Optical Co., Ltd. | Microscope pourvu d'organes d'observation et de prise de vues |
| DE19507203A1 (de) | 1995-03-02 | 1996-09-05 | Henkel Kgaa | Kosmetische und/oder pharmazeutische Zubereitungen |
| DE741187T1 (de) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
| US5635372A (en) | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
| US6132463A (en) * | 1995-05-19 | 2000-10-17 | Etex Corporation | Cell seeding of ceramic compositions |
| US5676976A (en) | 1995-05-19 | 1997-10-14 | Etex Corporation | Synthesis of reactive amorphous calcium phosphates |
| US6027742A (en) | 1995-05-19 | 2000-02-22 | Etex Corporation | Bioresorbable ceramic composites |
| US6117456A (en) | 1995-05-19 | 2000-09-12 | Etex Corporation | Methods and products related to the physical conversion of reactive amorphous calcium phosphate |
| US5760189A (en) | 1995-06-02 | 1998-06-02 | Genetics Institute, Inc. | Protein recovery & purification methods |
| WO1996039169A1 (fr) | 1995-06-05 | 1996-12-12 | Genetics Institute, Inc. | Procedes et compositions pour soigner et reparer les insertions du tissu conjonctif |
| CA2222626A1 (fr) | 1995-06-06 | 1996-12-12 | Biocoll Laboratories, Inc. | Materiaux osteogeniques modifies |
| US5902785A (en) | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US5674292A (en) | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| US5752974A (en) | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
| US6132214A (en) | 1995-12-18 | 2000-10-17 | Jouko Suhonen | Medical implant |
| KR20000064752A (ko) | 1996-03-22 | 2000-11-06 | 더 제네랄 호스피탈 코포레이션 | 중추신경계허혈또는외상의발현후폴리펩티드성장인자를투여하는방법 |
| US5700774A (en) | 1996-03-26 | 1997-12-23 | Genetics Institute, Inc. | Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same |
| ES2329953T3 (es) | 1996-04-19 | 2009-12-02 | Osiris Therapeutics, Inc. | Regeneracion e incremento de hueso utilizando celulas madre mesenquimales. |
| EP0907721A1 (fr) | 1996-05-28 | 1999-04-14 | Brown University Research Foundation | Charpentes biodegradables a base de hyaluronan destinees a la reparation tissulaire |
| US6133232A (en) | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| IT1288290B1 (it) | 1996-06-21 | 1998-09-11 | Fidia Spa In Amministrazione S | Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie |
| US5813411A (en) | 1996-08-20 | 1998-09-29 | Menlo Care, Inc. | Method of deforming tissue with a swollen hydrogel |
| US5965403A (en) | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
| AU4981797A (en) | 1996-10-11 | 1998-05-11 | Government Of The United States Of America, The | Isolation and method of using tissue growth-inducing frzb protein |
| JP4260891B2 (ja) | 1996-10-16 | 2009-04-30 | エテックス コーポレイション | 生体セラミック組成物 |
| AU6245898A (en) | 1997-01-21 | 1998-08-07 | Genetics Institute Inc. | Injectable formulations for treatment of osteoporotic bone |
| WO1998034951A1 (fr) | 1997-02-11 | 1998-08-13 | Amrad Operations Pty. Ltd. | Nouvelle famille de cytokines et utilisations correspondantes |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US20020098222A1 (en) | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US6001352A (en) | 1997-03-31 | 1999-12-14 | Osteobiologics, Inc. | Resurfacing cartilage defects with chondrocytes proliferated without differentiation using platelet-derived growth factor |
| US6610510B1 (en) | 1997-04-29 | 2003-08-26 | Regeneron Pharmaceuticals, Inc. | Morphogenic proteins |
| US5972368A (en) | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
| AU755657B2 (en) | 1997-07-04 | 2002-12-19 | University Of Utah Research Foundation | Lineage-restricted neuronal precursors |
| IT1296689B1 (it) | 1997-11-06 | 1999-07-14 | Fidia Advanced Biopolymers Srl | Derivati esterei dell'acido ialuronico aventi proprieta viscoelastiche e loro uso in campo biomedico-sanitario |
| US20030036629A1 (en) | 1997-12-12 | 2003-02-20 | Barry Foster | Novel tgf-beta protein purification methods |
| WO1999030632A1 (fr) | 1997-12-18 | 1999-06-24 | Comfort Biomedical, Inc. | Croissance osseuse d'implants prothetiques et autres |
| US20030170213A1 (en) | 1998-01-23 | 2003-09-11 | Marc F. Charette | Methods and compositions for enhancing cognitive function using morphogenic proteins |
| US20020076429A1 (en) | 1998-01-28 | 2002-06-20 | John F. Wironen | Bone paste subjected to irradiative and thermal treatment |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| IT1302534B1 (it) | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per |
| AU770196B2 (en) * | 1999-02-04 | 2004-02-12 | Warsaw Orthopedic, Inc. | Osteogenic paste compositions and uses thereof |
| PT1223990E (pt) | 1999-10-15 | 2004-12-31 | Fidia Advanced Biopolymers Srl | Formulacoes de acido hialuronico para administracao de proteinas osteogenicas |
| ES2233469T3 (es) | 1999-10-15 | 2005-06-16 | Genetics Institute, Llc | Formulaciones para la administracion de proteinas osteogenicas. |
| KR100485038B1 (ko) * | 2000-09-29 | 2005-04-22 | 혼다 기켄 고교 가부시키가이샤 | 2족보행 로봇 |
| CA2436162A1 (fr) * | 2001-01-25 | 2002-08-01 | John F. Wironen | Materiaux de greffe osseuse poreux injectables |
| TWI267378B (en) * | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| BR0310087A (pt) | 2002-05-17 | 2005-08-16 | Wyeth Corp | Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas |
-
2002
- 2002-05-23 TW TW091110889A patent/TWI267378B/zh not_active IP Right Cessation
- 2002-05-29 AR ARP020102004A patent/AR034347A1/es not_active Application Discontinuation
- 2002-05-31 US US10/160,607 patent/US7413753B2/en not_active Expired - Lifetime
- 2002-06-06 MX MXPA03011236A patent/MXPA03011236A/es active IP Right Grant
- 2002-06-06 EP EP02741855.7A patent/EP1404346B1/fr not_active Expired - Lifetime
- 2002-06-06 HU HU0401357A patent/HU230046B1/hu unknown
- 2002-06-06 CN CN2008100096136A patent/CN101239182B/zh not_active Expired - Lifetime
- 2002-06-06 KR KR10-2003-7016020A patent/KR20040019300A/ko not_active Ceased
- 2002-06-06 CA CA2449713A patent/CA2449713C/fr not_active Expired - Lifetime
- 2002-06-06 CA CA2852202A patent/CA2852202A1/fr not_active Abandoned
- 2002-06-06 JP JP2003503158A patent/JP4414218B2/ja not_active Expired - Lifetime
- 2002-06-06 PL PL367224A patent/PL216040B1/pl unknown
- 2002-06-06 EP EP10183027.1A patent/EP2260860B1/fr not_active Expired - Lifetime
- 2002-06-06 WO PCT/US2002/017798 patent/WO2002100331A2/fr not_active Ceased
- 2002-06-06 CN CNB028156390A patent/CN100379424C/zh not_active Expired - Lifetime
- 2002-06-06 NZ NZ530435A patent/NZ530435A/en not_active IP Right Cessation
- 2002-06-06 BR BRPI0210282A patent/BRPI0210282B8/pt not_active IP Right Cessation
- 2002-06-06 KR KR1020087018671A patent/KR100980164B1/ko not_active Expired - Lifetime
- 2002-06-06 KR KR1020107014777A patent/KR101105908B1/ko not_active Expired - Lifetime
- 2002-06-06 AU AU2002314928A patent/AU2002314928B2/en not_active Expired
- 2002-06-06 IL IL15913602A patent/IL159136A0/xx unknown
-
2003
- 2003-11-30 IL IL159136A patent/IL159136A/en active IP Right Grant
- 2003-12-03 NO NO20035383A patent/NO333548B1/no not_active IP Right Cessation
-
2004
- 2004-01-06 ZA ZA200400066A patent/ZA200400066B/en unknown
-
2007
- 2007-12-17 US US11/957,691 patent/US7622139B2/en not_active Expired - Lifetime
-
2009
- 2009-05-11 JP JP2009115064A patent/JP5091188B2/ja not_active Expired - Lifetime
- 2009-09-23 US US12/565,159 patent/US8003133B2/en not_active Expired - Fee Related
-
2010
- 2010-07-02 JP JP2010152516A patent/JP2010207653A/ja not_active Withdrawn
-
2013
- 2013-08-16 JP JP2013169050A patent/JP2013226469A/ja not_active Withdrawn
-
2014
- 2014-02-16 IL IL230994A patent/IL230994A0/en unknown
-
2016
- 2016-02-04 JP JP2016019546A patent/JP2016084361A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1404346B1 (fr) | Vecteurs d'apport de phosphate de calcium pour proteines osteoinductrices | |
| AU2002314928A1 (en) | Calcium phosphate delivery vehicles for osteoinductive proteins | |
| US6331312B1 (en) | Bioresorbable ceramic composites | |
| JP2007533376A (ja) | 遅延凝固リン酸カルシウムペースト | |
| EP2200537B1 (fr) | Administration avec du phosphate de calcium de facteurs de croissance et de différenciation à un os fragilisé | |
| AU2007203555B2 (en) | Calcium Phosphate Delivery Vehicles for Osteoinductive Proteins | |
| HK1062530B (en) | Calcium phosphate delivery vehicles for osteoinductive proteins | |
| HK1123502B (en) | Calcium phosphate delivery vehicles for osteoinductive proteins | |
| Dickenhorst | Preparation and characterization of DCPD-forming calcium phosphate cements and of cement-protein drug microparticle composites for bone tissue engineering |